Pure Biologics S.A. Logo

Pure Biologics S.A.

Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pure Biologics S.A. is a biopharmaceutical company focused on the discovery and development of novel biological drugs and non-systemic therapies. The company utilizes its expertise in antibody and aptamer technologies to develop new therapeutic molecules. Its development portfolio primarily targets immuno-oncology and autoimmune diseases. A key element of its strategy is the focus on creating entirely new biological drugs, as opposed to generic or biosimilar alternatives, positioning itself as an innovator in the biotechnology sector.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pure Biologics S.A. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 17:57
Share Issue/Capital Change
Podsumowanie emisji akcji serii P1 - Content (PL)
Polish 4.1 KB
2025-09-11 18:03
Report Publication Announcement
Zmiana terminu publikacji raportu półrocznego za I półrocze 2025 r. - Content (…
Polish 863 bytes
2025-09-10 18:43
Legal Proceedings Report
Wycofanie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.9 KB
2025-08-27 17:34
Share Issue/Capital Change
Przydział akcji zwykłych na okaziciela serii P1 - Content (PL)
Polish 954 bytes
2025-07-18 15:21
Share Issue/Capital Change
Zawarcie umowy inwestycyjnej z ACRX Investments Limited - Content (PL)
Polish 3.3 KB
2025-07-10 22:52
Regulatory News Service
Rejestracja akcji na okaziciela serii N w depozycie papierów wartościowych prow…
Polish 1.1 KB
2025-07-09 18:52
Share Issue/Capital Change
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.1 KB
2025-07-08 18:35
Share Issue/Capital Change
Treść uchwały nr 17 ZWZ z dnia 30 czerwca 2025 r.
Polish 156.3 KB
2025-07-08 18:35
Post-Annual General Meeting Information
Korekta raportu bieżącego nr 23/2025 w sprawie treści uchwał podjętych przez Zw…
Polish 1.7 KB
2025-06-30 18:05
Declaration of Voting Results & Voting Rights Announcements
Lista Akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish 1.5 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ Spółki w dniu 30 czerwca 2025 r.
Polish 352.3 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. 3…
Polish 766 bytes
2025-06-30 10:04
Capital/Financing Update
Rozpoczęcie negocjacji z ACRX Investments - Content (PL)
Polish 1.3 KB
2025-06-26 19:07
Legal Proceedings Report
Złożenie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.8 KB
2025-06-23 15:13
Regulatory News Service
Sprzedaż spółki DOTO MEDICAL sp. z o.o. oraz platformy aptamerowej - Content (P…
Polish 1.3 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.